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Abstract: 
Objective: Statins are effective in the primary and secondary prevention of cardiovascular events in 
individuals with and without diabetes mellitus. Emerging evidence, however, suggest that statins 
might reduce insulin sensitivity and secretion in healthy population as well as in type 2 diabetes. We 
wanted to investigate the effect of statin therapy introduction on insulin sensitivity in type 1 diabetes 
mellitus (T1DM) patients. 
Methods: This prospective observational 56 months long study included 832 randomly selected T1DM 
patients aged 25-61 years. Uncontrolled dyslipidemia and clinician perceived need for treatment, 
rather than randomization, was basis for individuals being started on either atorvastatin or simvastatin 
(10-40 mg); N=345, 41.47%. Patients on statin treatment were compared to those unexposed to statin. 
Insulin sensitivity was accessed using equation derived from euglycemic-hyperinsulinemic clamp 
studies estimated glucose disposal rate (eGDR).  
Results: Patients who started statin therapy (59.42% atorvastatin and 40.58% simvastatin) experienced 
a greater decrease in insulin sensitivity (19.27 % vs 12.82 % p<0.001) as well as metabolic control 
deterioration compared to statin free group.  The risk of decrease in insulin sensitivity attributable to 
statin use was 36.7% (HR 1.36 (95% CI 1.31, 1.43) after adjustment for age, gender, disease duration, 
smoking status and the concomitant antihypertensive therapy.   
Conclusion: Although there is still a lack of a clear molecular explanation on the adverse effects of 
statin therapy on insulin sensitivity, we showed that it deteriorates insulin sensitivity and metabolic 
control in type 1 DM. The cardiovascular benefits of statin treatment might outweigh the risk of 
developing insulin resistance, but the possible metabolic control worsening merits to be considered. 
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1. Introduction 
Statins represent a class of medications widely used in hypercholesterolaemia treatment (1). They act 
by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an intracellular 
enzyme which plays a central role in cholesterol production (2). Most statins are similar in structure to 
the enzyme’s substrate, HMG-CoA, and act as competitive inhibitors. Inhibition of this enzyme by 
statins translates into lowering low density lipoprotein (LDL)-cholesterol via enhanced LDL receptor 
expression (3, 4). As high LDL levels are causally associated with increased cardiovascular disease 
(CVD), statin treatment is effective in the primary and secondary prevention of CVD that is generally 
safe and well tolerated (5-8). Emerging evidence, however, suggest that long-term statin treatment is 
associated with type 2 diabetes mellitus (T2DM) occurrence (9-12). Although mechanisms underlying 
the association of statin therapy with diabetes remain unclear (13), recent data suggest that that statin 
treatment may increase the risk of T2DM due to decreases in both insulin sensitivity and insulin 
secretion (12).  
Although insulin resistance (IR) typically characterises T2DM, while the insulin deficiency is a 
primary defect in patients with type 1 diabetes mellitus (T1DM), there are suggestions that there is a 
certain degree of IR in T1DM (14, 15). The mechanisms of IR in T1DM is likely due to a combination 
of supraphysiologic levels of exogenous insulin and obesity. In the past, it was thought that IR in T1D 
was primarily related to hyperglycemia (16), however, it was recently proposed that adults with T1DM 
have both impaired glucose utilization and impaired insulin-induced non-esterified fatty acid 
suppression, independent of glycemic control (17). Skeletal muscle IR is a known feature of T1DM 
and is due to decreased glucose transport into myocytes from impaired insulin-stimulated upregulation 
of GLUT4 mRNA (18). 
The data linking statins with increase in IR are especially concerning since this class of drugs are used 
by millions of diabetic patients worldwide (19). Thus, it would be of special clinical interest to 
investigate the effect of statins on glycaemic control in T1DM patients without endogenous insulin 
secretion. Here we analysed the effect of statin therapy introduction on metabolic control and insulin 
sensitivity in T1DM patients during 56 months of prospective, observational follow-up.  
 
2. Methods 
Participants and clinical measurement at the baseline study  
The study was performed in 2010–2015 at the In-Patient Department of Diabetology of the Vuk 
Vrhovac University Hospital, Medical School University of Zagreb, Croatia and included 832 (345, 
41.47% starting statin treatment) randomly selected T1DM patients aged  25-61 years. Histories and 
complete physical examination and laboratory tests were performed in all subjects in order to exclude 
diseases other than T1DM or medications that might affect insulin sensitivity. Type 1 diabetes was 
defined by undetectable meal stimulated C-peptide concentrations (C-peptide <0.2 ng/mL) and 
positive islet cell and glutamic acid autoantibodies (at least from the previous medical record if the 
measurement was performed in our Clinic laboratory, respectively).  
The study was conducted according to the guidelines laid down in the Declaration of Helsinki and 
cleared by Merkur University Hospital Ethics Review Board for human studies. Written informed 
consent was obtained from and signed by all patients. 
Treatment and follow up 
The administration of each medicine, atorvastatin or simvastatin was determined by our In Patient 
clinic doctors to the patients with uncontrollable dyslipidaemia (total serum cholesterol and/or LDL 
cholesterol exceeding the reference range). The total serum cholesterol and LDL-cholesterol upper 
limits for the reference range in the consideration of statin therapy were 6 mmol/L and 3.0 mmol/L i.e. 
5.5 mmol/L and 2.5 mmol/L in the presence of other cardiovascular risk factors such as smoking, 
visceral obesity (waist circumference >80 cm for females and >102 cm for males) and hypertension. 
The begining of the follow up was defined as the administration date of each medicine, and the end of 
follow up was November 30, 2015. The study protocol consisted of every 14 months full check-up and 
measurements were identical to those of the baseline study. 
 
Anthropometric measurements and laboratory analysis 
Basic anthropometric measurements were performed as follows: waist circumference was measured on 
bare skin as the narrowest circumference between the 10th rib and the iliac crest while hip 
circumference was measured at the widest point of the gluteal muscles using a tailor measure and 
expressed in centimetres in order to calculate WHR. Weight was measured using a balanced beam 
scale with light clothing without shoes and expressed in kilograms (kg) and height was measured 
using a wallmounted stadiometer and expressed in centimeters (cm) in order to calculate BMI. Blood 
pressure was measured twice in the sitting position with a mercury sphygmomanometer after a resting 
period of 10 min (mmHg, reference interval 130/80). Fasting venous blood samples were collected for 
the determination of lipid profile status [total cholesterol (mmol/l, reference interval 5.0), HDL 
cholesterol (mmol/l, reference interval [1.0 for men, [1.3 for women), LDL cholesterol (mmol/l, 
reference interval\3.0), VLDL cholesterol (mmol/l), and triglycerides (mmol/l, reference interval\1.7)], 
HbA1c (%, reference interval 3.5–5.7).  HbA1c was measured spectrophotometrically by turbidimetric 
immuno-inhibition (Olympus AU600;p Beckman-Coulter, USA). Total serum cholesterol, HDL 
cholesterol and triglycerides in serum were measured by an HDL-C were estimated by homogenous 
enzymatic colorimetric method (20-22). LDL cholesterol was estimated using Friedewald formula: 
LDL-C = TC 2 HDL-C 2 TG/2.2  (mmol/L). In this formula, TG stands for triglycerides, and TG/2.2 
(or TG/5) serves as a proxy for VLDL  cholesterol. the ratio of the mass of triglyceride to that of 
cholesterol in VLDL is assumed to be relatively constant (23). 
 
 
 
Calculations 
Insulin sensitivity was calculated using the equation derived from euglycemic-hyperinsulinemic clamp 
studies-estimated glucose disposal rate (eGDR): 24.31–12.2X(WHR)–3.29X(AHT)–0.57X(HbA1c), 
where the units are mgkg
–1
min
–1
, WHR indicates the waist to hip ratio, AHT indicates blood pressure, 
and is expressed as: 0-no, 1-yes. Those on blood pressure medications or with blood pressure >140/90 
mmHg were considered to have hypertension, the equation was derived from a substudy of 24 EDC 
(Epidemiology of Diabetes Complications) participants who underwent euglycemic-hyperinsulinemic 
clamp studies (24). Lower eGDR levels indicate greater IR.  
 
Statistical analysis 
Statistical analyses were conducted using the SPSS version 17 (SPSS, Chicago, IL, USA). BMI, waist 
circumference, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, glucose and HbA1c 
levels and eGDR were log-transformed to correct for their skewed distribution. Baseline 
characteristics of the groups were compared using t test or χ2 test. The change in the numerical 
variables was accessed by ANOVA test followed by Bonferroni’s correction. HRs for the risk of  
eGDR decrease were calculated with Cox regression. Risk of eGDR decrease according to the type of 
statin (simvastatin, atorvastatin, vs no statin) study were calculated with Cox regression (Fig. 1.).  
Adjustments were made for age, BMI, waist circumference, current smoking, use of beta-blockers and 
use of diuretics.  A p value less than 0.05 was considered as statistically significant. 
3. Results 
Patients who started statin therapy (N= 345, 41.47%; 59.42% atorvastatin and 40.58% simvastatin) 
were older, had lower insulin sensitivity while higher rate of hypertension, i.e. they revealed higher 
rate of cardiovascular risk factors (Table 1.). They experienced a greater decrease in insulin sensitivity 
(19.27 % vs 12.82 % p<0.001) as well as metabolic control deterioration accounting for increase in 
body weight, HbA1c, total daily insulin requirement as well as blood pressure compared with statin 
free group despite the lipid profile amelioration  (Table 2).  There were no medication changes during 
the study period. The risk of decrease in insulin sensitivity attributable to statin use was 36.7% (HR 
1.36 (95% CI 1.31, 1.43) after adjustment for age, gender, disease duration, smoking status and the 
concomitant antihypertensive therapy (66% patients were using trandolapril, 26.5% bisoprolol and 
13.5% thiazide diuretics with no significant in-between group difference) (Figure 1a.).  The risk was 
significantly attributable to both atorvastatin (HR 1.34 (95% CI 1.27, 1.41) and simvastatin (HR 1.42 
(95% CI 1.34, 1.51), i.e. no significant difference in the risk of eGDR reduction was observed between 
two statins (Fig. 1.b.).  
4. Discussion 
We investigated the association of statin treatment with the risk of insulin sensitivity decrease as well 
as its effect on metabolic control in a cohort of T1DM patients during 56 months follow up. Our study 
reports several findings: 1) statin therapy introduction was associated with a 36% increased risk of 
reduced insulin sensitivity after adjustment for confounding factors; 2) no significant difference was 
found between atorvastatin and simvastatin on the risk of insulin resistance and 3) statin treatment was 
associated with an 
increase in HbA1C. 
Statins have a long track record of improving clinical outcomes in patients with high LDL cholesterol. 
Treatment of elevated LDL cholesterol levels with statins leads to a dramatic drop in the risk of heart 
attack, stroke, and death from CVD causes in individuals with and without diabetes mellitus (7). Over 
4 years, for every 1.03-mmol/L drop in the LDL cholesterol level, there is a 13% reduction in the risk 
of death from any cause in patients without diabetes mellitus and a 9% reduction in patients with 
diabetes mellitus (7). These beneficial effects of statins have been suggested in various stages of CVD 
process: statins have been implicated in plaque regression (25), plaque stabilization (26), reduction of 
inflammation (as noted by a reduction in C-reactive protein CRP levels) (27), reversal of endothelial 
dysfunction (28), and decreased thrombogenicity (29). They are thought to result from a reduction in 
proinflammatory nonsteroidal isoprenoid compounds synthesis through the inhibition of mevalonic 
acid processing by HMG-CoA reductase.  
Careful review of findings from many trials, however, shows that statins can raise plasma glucose 
concentration levels, and more patients who are on statin therapy are diagnosed with DM compared 
with those not on statins. Based on registry or prescription-based data, previous studies have reported 
that statin treatment was associated with higher risk of type 2 DM onset ranging from 10-46% (12, 30, 
31). In a collaborative meta-analysis of 13 randomised statin trials including in total nearly 90000 
participants, statin therapy was associated with a 9% increased risk for type 2 diabetes, based on 
fasting plasma glucose concentration values or physician reported diagnosis of diabetes (32).  The 
decrease in insulin sensitivity reflected by elevated levels of 2h plasma glucose is one of the proposed 
mechanisms explaining this co-incidence (12).  Although pancreatic β-cell destruction is a prominent 
feature of autoimmune diabetes, there is a growing number of patients with T1DM and IR who appear 
to be at increased risk of CVD mortality and development of diabetes related complications, a greater 
need for higher insulin doses, and multifactorial intervention, thus, more aggressive treatment (14, 15). 
To the best of our knowledge, the effect of statin therapy on insulin sensitivity in T1DM has not been 
evaluated so far. We clearly demonstrated that statin treatment in T1DM was associated with an 
increase in worsening glycemic control, an increase in blood pressure and reduction in insulin 
sensitivity during follow-up.  More importantly, statin treated group had a reduction in LDL-C in the 
first 14 months but then had a progressive increase back to baseline by the 56 month. LDL-cholesterol 
levels in statin-treated patients were off target at the end of the study whitch was and similar to the 
control group. It would appear that the most likely cause of this observation was lack of adherence to 
treatment. 
There are several cell-based studies using both adipocytes and muscle cells performed in order to 
understand the mechanism of statin induced insulin sensitivity decrease. Nakata et al. (2006) (33) 
suggested that statins inhibit isoprenoid biosynthesis which might lower insulin signaling proteins 
expression in adipocytes and thereby reduce glucose transporter expression or translocation (29). More 
recent, the potential causes of statin induced IR using a muscle cell based model system was 
performed (34). Based on their study research, simvastatin might cause IR through a novel fatty acid 
based mechanism independent of its cholesterol lowering effects. They hypothesized that by blocking 
HMG CoA reductase, simvastatin leads to accumulation of acetyl CoA, a precursor of fatty acid 
synthesis. Fatty acids are synthesized from acetyl-CoA and malonyl-CoA precursors, ant thus a 
potential consequence of treatment of cells with this drug is that it could lead to intracellular buildup 
of fatty acids. Free fatty acid accumulation is a known modulator of protein kinase-C (PKC) pathway 
because it interferes with insulin receptor substrate- 1 protein cascade and thus inhibits glucose uptake 
by Glut-4 transporter translocation.  It is important to point out here that the statin’s effect on IR has 
been reported in patients with distinct statins suggesting that the effect is tied to their mechanism of 
action, i.e HMG CoA reductase inhibition and is not an off target effect. 
The present study has a number of potential limitations. First, it was observational, which limited our 
ability of full patient randomisation and thus infers a full causal relation between statin tratment and 
the decrease in insulin sensitivity in T1DM patients. The groups (statin and no statin group) were not 
matched and although these differences were taken into account during the statistical analysis, the 
statin group was "metabolically unhealthier" than the no statin group. Both groups demonstrated 
deterioration in insulin sensitivity, but individuals that have a degree of uncontrolled dyslipidemia, 
with perceived need for treatment, were more prone to progressive IR than those who do not. That is 
to say, inadvertently some bias was introduced into these 2 group comparisons. The observed 
differences in the two groups might predict more progressive IR in the statin-treated group. However, 
this does not detract from our observation, but rather supports concept that statin-induced deterioration 
of insulin sensitivity is more likely to occur in individuals with IR. Second, we measured insulin 
sensitivity using clinical parameters with eGDR and did not have access to direct, detailed measures of 
insulin resistance using euglycemic-hyperinsulinemic clamp test. Third, although there were no 
medication changes during the study period, illness, lifestyle changes, treatment adherence could have 
affected the obtained results. 
However, we showed that statins may increase the deterioration in insulin sensitivity and metabolic 
control in T1DM. The cardiovascular benefits of statin treatment might outweigh the risk of worsening 
IR, however the risk and benefit must be considered..  
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Figure 1.a) Risk of insulin sensitivity decrease by statin treatment during 56 months follow up 
Legend: vertical line indicates hazard ratio (HR); black line-statin treated group (N=345); grey line-
statin free group (N=487) 
Figure 1.b) Risk of insulin sensitivity decrease by atorvastatin and simvastatin treatment group during 
56 months follow up 
 
Legend: vertical line indicates hazard ratio (HR); black continuous line-atorvastatin (N=205), black 
dotted line simvastatin (N=140). 
 
 
Table 1. Baseline comparisons of statin-free group versus statin-treated group 
Characteristics No statin (N=487) Statin (N=345) p   
Age (years) 38±11 41±6 <0.001   
Disease duration (years) 15.35±10.64 18.53±7.12 <0.001   
Current smoker (%) 15.81 26.37 <0.001   
Waist (cm) 83.09±10.5 85.99±12.41 0.001 
BMI (kg/m
2
) 24.42±3.62 25.12±3.07 0.002 
HbA1c (%) 7.38±1.07 7.24±1.42 0.105 
eGDR (mg kg
−1
 min
−1
) 9.75±2.03 9.36±2.88 0.023 
Total daily insulin dose 
(IU/kg) 
0.601±0.020 0.651±0.031 <0.001 
Total cholesterol 
(mmol/L) 
5.04±0.95 5.01±0.75 0.625 
LDL-cholesterol 
(mmol/L) 
2.82±0.77 2.89±0.82 0.209 
HDL cholesterol 
(mmol/L) 
1.68±0.43 1.66±0.39 0.493 
Triglycerides (mmol/L) 1.07±0.64 1.08±0.06 0.772 
Statin dose (N, patients): 
atorvastatin 10 mg 
atorvastatin 20 mg 
atorvastatin 40 mg 
simvastatin 10 mg 
simvastatin 20 mg 
simvastatin 40 mg 
 
- 
- 
- 
- 
- 
- 
 
24 
180 
2 
6 
131 
2 
 
 
 
--- 
  
Systolic blood pressure 
(mmHg) 
127.76±12.33 131.13±14.5 0.001 
Diastolic blood pressure 
(mmHg) 
81.16±8.6 82.45±6.10 0.017 
Legend:*between group comparison; two sided t-test 
  
Table 2. Comparison of clinical and biochemical risk factors between type 1 diabetes mellitus individuals by starting statin treatment during the study period 
Characteris
tics 
No statin (N=487) Statin (N=345) p  
 Baseline 14
th
 
month 
28
th
 
month 
42
nd
 
month 
End of 
follow up 
Baseline 14
th
 
month 
28
th
 
month 
42
nd
 
month 
End of 
follow up 
 
Waist (cm) 83.09±10.
5 
83.23±11.
5 
83.91±9.4 83.9±10.0 84.13±11.
0 
85.77±10
.75 
 
85.99±12.
41 
86.56±11.
62 
87.83±10.
51 
88.29±12.
68 
**0.133  
***0.03
6 
BMI 
(kg/m
2
) 
24.42±3.6
2 
24.81±2.5
5 
24.93±4.1
2 
24.97±3.6
1 
25.04±3.6
5 
25.12±3.
07 
25.58±2.0
1 
25.82±3.0
1 
26.01±2.0
3 
26.74±1.0
6 
**0.007 
***<0.0
01 
HbA1c 
(%) 
7.38±1.07 7.35±1.81 7.32±1.46 7.30±0.91 7.28±1.02 7.24±1.4
2 
7.44±1.53 7.32±1.37 7.41±1.12 7.56±1.74 **0.136 
***0.00
5 
eGDR (mg 
kg
−1
 
min
−1
) 
9.75±2.03 9.41±1.97  9.37±1.49 8.89±2.01 8.5±2.22 9.36±2.8
8 
8.56±1.79 8.19±1.03 8.03±0.91 8.04±2.29 **0.24 
***0.00
4 
Total daily 
insulin 
dose 
(IU/kg) 
0.601±0.0
20 
0.608±0.0
51 
0.603±0.0
33 
0.604±0.0
55 
0.604±0.0
31 
0.651±0.
031 
0.675±0.0
33 
0.692±0.0
11 
0.705±0.0
21 
0.722±0.0
12 
**0.073 
***0.00
1 
Total 
cholesterol 
(mmol/L) 
4.92±0.82 4.94±0.94 4.97±0.83 5.04±0.95 5.14±0.67 5.01±0.7
5 
4.46±1.1 4.69±0.89 4.96±0.81 4.96±0.93 **0.06 
***0.00
5 
LDL-
cholesterol 
(mmol/L) 
2.78±0.81 2.82±0.77 2.77±0.79 2.79±0.69 2.86±0.69 2.89±0.8
2 
2.13±0.79 2.57±0.87 2.61±0.69 2.87±0.74 **0.39 
***0.73 
HDL 
cholesterol 
(mmol/L) 
1.68±0.43 1.65±0.42 1.68±0.55 1.78±0.39 1.69±0.39 1.66±0.3
9 
1.55±0.42 1.48±0.39 1.55±0.86 1.57±0.91 **0.71 
***0.07 
Triglyceri
des 
(mmol/L) 
1.07±0.64 1.14±0.72 1.01±0.64 0.98±0.49 1.06±0.55 1.08±0.0
6 
1.23±0.71 1.15±0.20 1.11±0.61 1.17±0.72 **0.79 
***0.02 
Systolic 
blood 
127.76±12
.33 
124.24±15
.76 
124.48±15
.97 
127.83±13
.69 
128.28±19
.88 
131.13±1
4.5 
132.42±17
.62 
131.68±15
.61 
135.85±11
.91 
133.43±10
.73 
**0.565 
***0.02
pressure 
(mmHg) 
1 
Diastolic 
blood 
pressure 
(mmHg) 
78.45±8.4
2 
78.08±8.6
4 
81.16±8. 77.5±8.37 81.93±5.1
9 
82.45±6.
10 
84.42±9.4
7 
87.75±9.4
5 
88.57±8.6
1 
86.56±7.1
6 
**0.091  
***0.00
1 
Legend:*between group comparison; **ANOVA test for the group of patients without statins followed by Bonferroni’s correction; *** ANOVA test for the group of patients on statins followed by 
Bonferroni’s correction 
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